Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chubb
Medtronic
Cipla
Federal Trade Commission
Julphar

Generated: August 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,795,604

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,795,604 protect, and when does it expire?

Patent 9,795,604 protects IMBRUVICA and is included in two NDAs.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 9,795,604
Title:Methods of treating and preventing graft versus host disease
Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s): Byrd; John C. (Columbus, OH), Dubovsky; Jason A. (Columbus, OH), Muthusamy; Natarajan (Galloway, OH), Johnson; Amy Jo (Dublin, OH), Miklos; David (Stanford, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/523,650
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,795,604
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,795,604

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-002 Feb 16, 2018 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-003 Feb 16, 2018 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-004 Feb 16, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,795,604

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 098208 ➤ Sign Up
Australia 2014339815 ➤ Sign Up
Canada 2928721 ➤ Sign Up
China 106102745 ➤ Sign Up
Eurasian Patent Organization 201690745 ➤ Sign Up
European Patent Office 3060218 ➤ Sign Up
Israel 245183 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Merck
Teva
Cantor Fitzgerald
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.